Objective: The pleiotropic functions of statins are crucial in reducing cardiovascular events. There is controversy about their effects on insulin resistance. The aim of this study was to investigate the effect of Fluvastatin treatment on plasma adiponectin and insulin levels in a group of dyslipidemic population who had no confounding factors for insulin resistance such as diabetes or hypertension.
Design and methods: Forty nine (27 male, 22 female; mean age 47.2±10.3 years; BMI 29.64±3.2 kg/m2) consecutive patients and 20 control subjects (6 male, 14 female; mean age 45.3±9.31 years; BMI 30.07±4.04 kg/m2) were enrolled. Patients were treated with therapeutic lifestyle changes (TLC) for six weeks. Then, the follow up was maintained for additional 12 weeks in the remaining 43 patients. The remaining patients were allocated to Fluvastatin 80 mg daily plus TLC (24 patients; 14 male and 10 female) or to TLC alone (19 patients; 9 male and 10 female). The insulin sensitivity index was quantified using homeostasis model assessment index (HOMA). The local ethic committee of university approved the study protocol and informed consent was obtained from all subjects.
Results: TLC caused significant improvement in plasma insulin levels and HOMA indexes (P=0.02 and P=0.02 respectively) along with a significant elevation of plasma adiponectin levels (P=0.002). Fluvastatin treatment made significant contributions on the decrement of total cholesterol, LDL cholesterol (P=0.001, P=0.003 respectively) and the elevation of plasma adiponectin levels (P=0.001). However, no significant effect of Fluvastatin treatment was established on plasma insulin or HOMA level.
Conclusions: These results indicate that Fluvastatin treatment has no effect on insulin sensitivity while it causes significant elevation in plasma adiponectin levels.
01 - 05 Apr 2006
European Society of Endocrinology